BackArcturus Therapeutics Holdings Overview

Arcturus Therapeutics Holdings Total Current Liabilities

Track Arcturus Therapeutics Holdings's total current liabilities ($34M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$34.37M
30.44% YoYΔ $-15.04M vs prior year quarter

Peer average

Loading

Arcturus Therapeutics Holdings Total Current Liabilities History

Loading

Arcturus Therapeutics Holdings vs. peers: Total Current Liabilities Comparison

Loading

Arcturus Therapeutics Holdings Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Arcturus Therapeutics Holdings (ARCT) FAQ

Arcturus Therapeutics Holdings's total current liabilities stands at $34M as of March 2026. That compares with $49M in the prior-year period — down 30.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Arcturus Therapeutics Holdings reported $34M in total current liabilities versus $49M a year earlier — a 30.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $49M in the prior-year period — down 30.4% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Arcturus Therapeutics Holdings's total current liabilities evolved across reporting periods, while the comparison chart places ARCT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Arcturus Therapeutics Holdings's reading of $34M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.